---
title: "HanAll Biopharma is forecast to post 2026 revenue of 169.3 billion KRW, operating profit of 12.0… — report author — DecisionGateway"
description: "prediction by report author, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1d4b6-f715-7150-a782-62a08f93decd"
meta:
  "og:description": "prediction by report author, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "HanAll Biopharma is forecast to post 2026 revenue of 169.3 billion KRW, operating profit of 12.0… — report author — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

prediction

# **HanAll Biopharma is forecast to post 2026 revenue of 169.3 billion KRW, operating profit of 12.0 billion KRW, and an operating margin of 7.1%.**

A prediction by report author. Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *2026년 매출 169.3십억원 / 영업이익 12.0십억원 / 영업이익률 7.1%*

companyreportPublished 2026-11-10 [ Read source](https://t.me/companyreport/116013)

## **Related claims**

[**HanAll Biopharma is forecast to post 2027 revenue of 177.3 billion KRW, operating profit of 10.6 billion KRW, and an operating margin of 6.0%.**report author · prediction](https://dgw.tmarket.io/claims/01a1d4b6-f723-73df-9e13-66f79ab9d480) [**RFHIC's financial forecasts are: 2025 revenue 185.8 billion won, operating profit 30.9 billion won, operating margin 16.6%; 2026 revenue 262.1 billion won, operating profit 62.7 billion won, operating margin 23.9%; 2027 revenue 318.0 billion won, operating profit 75.3 billion won, operating margin 23.7%.**report author · prediction](https://dgw.tmarket.io/claims/01a1d4b2-5523-7647-9b7d-c1785207abca) [**2026 consolidated revenue is forecast at 4.5459 trillion KRW and operating profit at 1.263 trillion KRW.**하나증권 · prediction](https://dgw.tmarket.io/claims/01a1ceb7-a45b-7998-be7c-50de98f3da82) [**Q4 2026 results are forecast at revenue of 510.2 billion KRW (YoY +3%, QoQ -9%) and an operating loss of 10.3 billion KRW, a swing to loss for the first time in eight quarters.**하나증권 · prediction](https://dgw.tmarket.io/claims/01a1ceab-6463-7f11-8a87-35245e685baf) [**2026년 매출 7,156.1십억원 / 영업이익 782.0십억원 / 영업이익률 10.9%를 기록할 것으로 전망된다.**리포트 작성자 · prediction](https://dgw.tmarket.io/claims/01a1d4aa-cf6a-7f8d-9763-ad34284964dc) [**2026년 매출 3,853.2억원 / 영업이익 403.4억원 / 영업이익률 10.47%가 예상된다.**companyreport · prediction](https://dgw.tmarket.io/claims/01a1d4a7-cb31-73f8-885b-2771264ac849)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 3,800+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1d4b6-f715-7150-a782-62a08f93decd#webpage","@type":"WebPage","description":"prediction by report author, recorded recently — verbatim quote and source citation.","name":"HanAll Biopharma is forecast to post 2026 revenue of 169.3 billion KRW, operating profit of 12.0… — report author — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1d4b6-f715-7150-a782-62a08f93decd","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1d4b6-f715-7150-a782-62a08f93decd#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1d4b6-f715-7150-a782-62a08f93decd"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1d4b6-f715-7150-a782-62a08f93decd#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"HanAll Biopharma is forecast to post 2026 revenue of 169.3…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1d4b6-f715-7150-a782-62a08f93decd#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-10","isBasedOn":"https://t.me/companyreport/116013","text":"2026년 매출 169.3십억원 / 영업이익 12.0십억원 / 영업이익률 7.1%","url":"/claims/01a1d4b6-f715-7150-a782-62a08f93decd"}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.